229 related articles for article (PubMed ID: 27644242)
1. Effects of a Novel Fixed Combination of Nutraceuticals on Serum Uric Acid Concentrations and the Lipid Profile in Asymptomatic Hyperuricemic Patients : Results from the PICONZ-UA Study.
Rozza F; Trimarco V; Izzo R; Grassi D; Ferri C
High Blood Press Cardiovasc Prev; 2016 Dec; 23(4):381-386. PubMed ID: 27644242
[TBL] [Abstract][Full Text] [Related]
2. [Other antihyperuricemic agents].
Ogino K; Igawa O; Hisatome I
Nihon Rinsho; 2008 Apr; 66(4):754-7. PubMed ID: 18409527
[TBL] [Abstract][Full Text] [Related]
3. [Effects of micronized fenofibrate on lipid and uric acid metabolism in patients with hyperlipidemia].
Li LJ; Chen H; Ren JY; Wang L; Luo Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Oct; 41(5):541-4. PubMed ID: 19829670
[TBL] [Abstract][Full Text] [Related]
4. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
[TBL] [Abstract][Full Text] [Related]
5. Elevated serum leptin concentrations in women with hyperuricemia.
Matsubara M; Chiba H; Maruoka S; Katayose S
J Atheroscler Thromb; 2002; 9(1):28-34. PubMed ID: 12238635
[TBL] [Abstract][Full Text] [Related]
6. Epidemiological association between uric acid concentration in plasma, lipoprotein(a), and the traditional lipid profile.
Lippi G; Montagnana M; Luca Salvagno G; Targher G; Cesare Guidi G
Clin Cardiol; 2010 Feb; 33(2):E76-80. PubMed ID: 20043336
[TBL] [Abstract][Full Text] [Related]
7. Topiroxostat influences circulating lipid concentrations in hyperuricemic patients
.
Tohyo S
Int J Clin Pharmacol Ther; 2019 Nov; 57(11):567-570. PubMed ID: 31496508
[TBL] [Abstract][Full Text] [Related]
8. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R
J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study.
Hosoya T; Sasaki T; Hashimoto H; Sakamoto R; Ohashi T
J Clin Pharm Ther; 2016 Jun; 41(3):298-305. PubMed ID: 27079434
[TBL] [Abstract][Full Text] [Related]
10. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
[TBL] [Abstract][Full Text] [Related]
11. The comparison of dyslipidemia and serum uric acid in patients with gout and asymptomatic hyperuricemia: a cross-sectional study.
Liang J; Jiang Y; Huang Y; Song W; Li X; Huang Y; Ou J; Wei Q; Gu J
Lipids Health Dis; 2020 Mar; 19(1):31. PubMed ID: 32127000
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study.
Hosoya T; Sasaki T; Ohashi T
Clin Rheumatol; 2017 Mar; 36(3):649-656. PubMed ID: 27832384
[TBL] [Abstract][Full Text] [Related]
13. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy.
Farnier M; Ducobu J; Bryniarski L
Curr Med Res Opin; 2011 Nov; 27(11):2165-73. PubMed ID: 21973199
[TBL] [Abstract][Full Text] [Related]
15. Time to target uric acid to retard CKD progression.
Kumagai T; Ota T; Tamura Y; Chang WX; Shibata S; Uchida S
Clin Exp Nephrol; 2017 Apr; 21(2):182-192. PubMed ID: 27339448
[TBL] [Abstract][Full Text] [Related]
16. Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial.
Panahi Y; Kianpour P; Mohtashami R; Jafari R; Simental-Mendía LE; Sahebkar A
J Cardiovasc Pharmacol; 2016 Sep; 68(3):223-9. PubMed ID: 27124606
[TBL] [Abstract][Full Text] [Related]
17. Treatment of asymptomatic hyperuricemia and prevention of vascular disease: a decision analytic approach.
Akkineni R; Tapp S; Tosteson AN; Lee A; Miller KL; Choi HK; Zhu Y; Albert DA
J Rheumatol; 2014 Apr; 41(4):739-48. PubMed ID: 24584921
[TBL] [Abstract][Full Text] [Related]
18. Acupuncture for serum uric acid in patients with asymptomatic hyperuricemia: A randomized, double-blind, placebo-controlled trial.
Huang Y; Meng J; Sun B; Xiang T; Zhou X; Xu B; Wu Y; Chen Z; Zhang S
Int J Cardiol; 2017 Apr; 232():227-232. PubMed ID: 28087178
[TBL] [Abstract][Full Text] [Related]
19. Prednisone in Uric Acid Lowering in Symptomatic Heart Failure Patients with Hyperuricemia -- The PUSH-PATH3 Study.
Meng H; Liu G; Zhai J; Zhen Y; Zhao Q; Zheng M; Ma G; Wang L; Tian L; Ji L; Duan L; Li L; Liu K; Liu C
J Rheumatol; 2015 May; 42(5):866-9. PubMed ID: 25774058
[TBL] [Abstract][Full Text] [Related]
20. A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients.
Pichholiya M; Yadav AK; Luhadia SK; Tahashildar J; Aseri ML
Indian J Pharmacol; 2016; 48(5):522-525. PubMed ID: 27721537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
